Meta AnalysisID 3745
黄嘌呤氧化酶抑制剂在有卒中病史患者中的作用：一项系统评价
CRD42016053877
Are xanthine oxidase inhibitors safe and effective for improving vascular function and outcomes in patients with history of stroke.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 3745
- Evidence Id
- 12303
- Core Evidence Id
- 12303
- Source Meta Analysis Id
- 3705
- Herb2 Meta Analysis Id
- HBMA003705
- Crd Id
- CRD42016053877
- Title
- The role of xanthine oxidase inhibitors in patients with history of stroke: a systematic review
- Review Question
- Are xanthine oxidase inhibitors safe and effective for improving vascular function and outcomes in patients with history of stroke.
- Study Type Included
- We will include randomized, controlled, double-blinded trials that assess the use of allopurinol in patients with past history of stroke versus placebo.
- Condition Being Studied
- Stroke
- Participant
- Inclusion: > 18 years of age, previous history of stroke (ischemic, hemorrhagic, or transient ischemic attack)
- Animal
- Human Disease Modelled
- Intervention
- Xanthine oxidase inhibitors (XOI), such as allopurinol and febuxostat, are commonly used to lower SUA levels in patients with gout and cancer therapy-induced hyperuricemia. As epidemiologic studies have suggested that high SUA is associated with cardiovascular risk, XOI have been studied for their possible role in risk reduction and improved outcomes. Allopurinol is the most studied XOI for this indication. However, the potential mechanism of allopurinol in this role may not stem from its SUA lowering effects. Rather, it is hypothesized that allopurinol reduces vascular oxidative stress by blocking the formation of radical oxygen species (ROS) associated with the activity of xanthine oxidase. Given its demonstrated effects on endothelial function in a variety of cardiovascular disease states, allopurinol is a promising treatment for patients with history of stroke. This relatively inexpensive medication is very well tolerated within the normal dosing range of 100-300 mg daily, with the majority of adverse effects being rash, diarrhea, nausea, increased hepatic enzymes, and increased acute gout attacks.
- Comparator Control
- Placebo
- Main Outcome
- Change in markers of arterial stiffness (augmentation index, PWV)
- Outcome Measure
- Additional Outcome
- Change in markers of inflammation (ICAM-1, CRP, IL-6) Change in uric acid levels Change in disability as measured by the modified Rankin Scale
- Study Method
- Systematic review
- Keyword
- Enzyme Inhibitors; Gout Suppressants; Humans; Stroke; Xanthine Oxidase
- Contact
- Dr Britnell [email protected]
- Organisational Affiliation
- Funding Source
- No funding
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- United States of America
- Review Stage
- Review Ongoing
- First Submission Date
- Registration Date
- 2016-12-21
- Anticipated Start Date
- 2016-12-13
- Anticipated Completion Date
- 2017-02-28
- Title Cn
- 黄嘌呤氧化酶抑制剂在有卒中病史患者中的作用：一项系统评价
- Title En
- The role of xanthine oxidase inhibitors in patients with history of stroke: a systematic review
- Bilingual Status
- complete